Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients

NCT02514239 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
43
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Boehringer Ingelheim